Reimbursement data by testing indications (e.g., ICD-10 codes for depression, anxiety, GERD) is needed to educate patients on which insurance providers are generally reimbursing for CYP2C19, CYP2D6, and/or panel testing. This evidence concerns the gene CYP2C19 and gastroesophageal reflux disease.